Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Study purpose: To evaluate the efficacy and safety of Tislelizumab in combination with advanced hepatocellular carcinoma in the real world; Study design: Non-intervention, single center, case registration, real-world study; Number of registrations: 40; Source of data: This project is a non-interventionary real world case follow-up registration. All registration data are from real clinical practice cases. The collected data include the following requirements: 1. Age ≥18 years old; 2. Unresectable hepatocellular carcinoma confirmed by histological examination or clinical diagnosis; 3. Plan or have received systemic therapy combined with Tiralizumab; 4. No participation in other clinical studies; 5. Access to Tislelizumab treatment and other clinical records; Primary endpoint: Overall response rate; Secondary endpoint: Disease control rate, progress free survival, overall survival, safety; Exploratory endpoint: To explore the predictive value of multiple Biomarker combinations, such as PD-L1, TMB, MSI, DDR, POLE/POLD, in HCC immunotherapy response.

Sex

All

Minimum age

18 Years

This project is a non-interventionary real world case follow-up registration. All registration data are from real clinical practice cases. The collected data include the following requirements:

1. Age ≥18 years old;
2. Unresectable hepatocellular carcinoma confirmed by histological examination or clinical diagnosis;
3. Plan or have received systemic therapy combined with Tislelizumab;
4. No participation in other clinical studies;
5. Access to Tislelizumab treatment and other clinical records.